Pear Therapeutics, Inc. (PEAR): Price and Financial Metrics

PEAR POWR Grades

• Sentiment is the dimension where PEAR ranks best; there it ranks ahead of 88.24% of US stocks.
• The strongest trend for PEAR is in Growth, which has been heading up over the past 178 days.
• PEAR's current lowest rank is in the Growth metric (where it is better than 5.87% of US stocks).

PEAR Stock Summary

• With a one year PEG ratio of 0.45, PEAR THERAPEUTICS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than merely 5.03% of US stocks.
• As for revenue growth, note that PEAR's revenue has grown 172.08% over the past 12 months; that beats the revenue growth of 95.67% of US companies in our set.
• PEAR THERAPEUTICS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -265.61%, greater than the shareholder yield of only 2.46% of stocks in our set.
• If you're looking for stocks that are quantitatively similar to PEAR THERAPEUTICS INC, a group of peers worth examining would be VIAV, IBIO, VNDA, EGAN, and ALKS.
• To dig deeper into the stock's financial statements, go to PEAR's page on browse-edgar?action=getcompany&CIK=0001835567.

PEAR Valuation Summary

• In comparison to the median Technology stock, PEAR's EV/EBIT ratio is 112.7% lower, now standing at -2.4.
• Over the past 26 months, PEAR's price/sales ratio has gone down 20.

Below are key valuation metrics over time for PEAR.